학술논문
An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics.
Document Type
Report
Author
Source
mAbs; Jan-Dec 2021, Vol. 13 Issue 1, p1-19, 19p
Subject
Language
ISSN
19420862